p. 867−880
2476-762X
Vol.21/No.4
p. 881−895
2476-762X
Vol.21/No.4
p. 897−901
2476-762X
Vol.21/No.4
p. 903−909
2476-762X
Vol.21/No.4
p. 911−917
2476-762X
Vol.21/No.4
p. 919−926
2476-762X
Vol.21/No.4
p. 927−934
2476-762X
Vol.21/No.4
p. 935−941
2476-762X
Vol.21/No.4
p. 943−951
2476-762X
Vol.21/No.4
p. 953−960
2476-762X
Vol.21/No.4
p. 961−966
2476-762X
Vol.21/No.4
p. 967−974
2476-762X
Vol.21/No.4
p. 975−982
2476-762X
Vol.21/No.4
p. 983−991
2476-762X
Vol.21/No.4
p. 993−996
2476-762X
Vol.21/No.4
p. 997−1003
2476-762X
Vol.21/No.4
p. 1005−1009
2476-762X
Vol.21/No.4
p. 1011−1018
2476-762X
Vol.21/No.4
p. 1019−1023
2476-762X
Vol.21/No.4
p. 1025−1029
2476-762X
Vol.21/No.4
C SNP of XRCC1 gene polymorphism was performed by (PCR-RFLP) technique. Results: A statistically higher frequency of XRCC1 (CC, GC) genotypes and increased (C) allele frequency in patients with HCC was found in comparison to cirrhotic HCV patients as well as control group. In addition, patients with the XRCC1 (CC, GC) genotypes had significantly higher number and larger size of tumor foci and significantly higher Child Pugh grades. Multivariate analysis showed that the presence of c.1517G>C SNP of XRCC1 gene is an independent risk for the development of HCC in chronic HCV patients with 3.7 fold increased risk of HCC development. In conclusion: XRCC1 gene polymorphism could be associated with increased risk of HCC development in chronic HCV Egyptian patients. ]]>
p. 1031−1037
2476-762X
Vol.21/No.4
p. 1039−1044
2476-762X
Vol.21/No.4
p. 1045−1050
2476-762X
Vol.21/No.4
p. 1051−1056
2476-762X
Vol.21/No.4
p. 1057−1061
2476-762X
Vol.21/No.4
p. 1063−1068
2476-762X
Vol.21/No.4
0.05). Conclusion: This study concluded that smoking, including cigarette and shisha, even passive smoking harmed health through increasing Malondialdehyde, serum IgE and hs-CRP levels in the body.]]>
p. 1069−1072
2476-762X
Vol.21/No.4
p. 1073−1080
2476-762X
Vol.21/No.4
p. 1081−1087
2476-762X
Vol.21/No.4
p. 1089−1096
2476-762X
Vol.21/No.4
p. 1097−1102
2476-762X
Vol.21/No.4
50% and c-Myc > 40% and demonstrating the overall frequency of double expressers as 14.8%. The prognosis of the mentioned cases was extremely poor, median survival of 10 months. Conclusion: The concurrent expression of Bcl-2 and c-Myc was found to be 14% (level of expression for Bcl-2 > 50% and c-Myc > 40%) which is potentially a significant health burden and an emerging threat.]]>
p. 1103−1107
2476-762X
Vol.21/No.4
p. 1109−1114
2476-762X
Vol.21/No.4
p. 1115−1119
2476-762X
Vol.21/No.4
p. 1121−1127
2476-762X
Vol.21/No.4
p. 1129−1134
2476-762X
Vol.21/No.4
2 cm accounted for 71.31% of cases, Lymph node metastases were available in 57.86% cases. Most patients were diagnosed at stage II (59.18%). The majority of patients were classified as moderate Nottingham prognostic index (54.9%). Estrogen receptor and Progesterone receptor were positive in 53.16% and 50.63%, respectively. 76.37% of cases were in high expression group of Ki-67 (≥14%). HER2 IHC 2+, 3+ were accounted for 28.69% and HER2 gene amplification was detected in 31% cases. HER2 gene amplification and/or overexpression was significantly associated with cell proliferation index Ki67. Furthermore, HER2 gene expression tended to be more frequently found in tumors with large tumor size, high grade, high stage and high Nottingham prognostic index and confirmed their prognostic independent role. Conclusions: Our data indicated that HER2 gene expression was significantly correlated with cell proliferation index Ki67, but not significantly associated with another clinicopathological factors in breast cancer of Vietnamese women. ]]>
p. 1135−1142
2476-762X
Vol.21/No.4
p. 1143−1148
2476-762X
Vol.21/No.4
p. 1149−1154
2476-762X
Vol.21/No.4
p. 1155−1162
2476-762X
Vol.21/No.4
p. 1163−1166
2476-762X
Vol.21/No.4
p. 1167−1172
2476-762X
Vol.21/No.4